Individualizing chemotherapy for solid tumors - Is there any alternative?

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 541-548

  Cree, Ian A ^a   Kurbacher, Christian M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ATP; Chemosensitivity; Chemotherapy; In vitro; Luminescence; Prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; HUMAN; LUMINESCENCE; PREDICTION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030764194     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00001     Document Type: Review

References (78)

1. Mattieu M-C, Koscielny S, Le Bihan M-L, Spielman M, Arriagada R. p53 protein overexpression and chemoresistance in breast cancer. Lancet 1995; 345: 1182.
2. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Veli-Matti K, Syrjanen K. Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995; 177: 225-32.
3. Loeb LA, Christians FC. Multiple mutations in human cancers. Mutat Res 1996; 350: 279-86.
4. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386: 761-3.
5. Petty RD, Sutherland LA, Hunter EM, et al. Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity. Biophys Biochem Res Commun 1994; 199: 264-70.
6. Hunter EM, Sutherland IA, Cree IA, Dewar JA, Precce PE, Andreotti PE. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19: 242-9.
7. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anti-cancer agents in cells lacking p21. Nature 1996; 381: 713-6.
8. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997; 385: 123-5.
9. Lane DP. p53: guardian of the genome. Nature 1992; 362: 786-7.
10. Riggs CE, Bennett, JP. Combination Chemotherapy. In: Moosa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology, 2nd edn. Baltimore: Williams & Wilkins 1991: 565-8.
11. Fennelly D, Wasserheit C, Schneider J, et al. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial. Cancer Res 1994; 54: 6137-42.
12. Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res: in press.
13. Bosari S, Viale G, Radaelli T, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinoma and its prognostic implications. Hum Pathol 1993; 24: 1175-9.
14. Niwa N, Itoh M, Murase T, Itoh N, Mori H, Tamaya T. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-7.
15. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-38.
16. van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
17. Antman K, Ayash L, Elias A, et al. High dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy: analysis by age. Monogr Natl Cancer Inst 1994; 16: 91 4.
18. Stewart THM, Retsky MW, Tsai SCJ, Verma S. Dose response in the treatment of breast cancer. Lancet 1994; 343: 402-4.
19. Leonard RC. The importance of dose and schedule in cancer chemotherapy: breast cancer. Anti-Cancer Drugs 1995; 6 (suppl 5): 17-27.
20. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumor chemosensitivity assay: differences in sensitivity between cultured tumor cell lines and clinical studies. J Biolum Chemilum 1994; 9: 373-8.
21. Cree IA, Pazzagli M, Mini E, et al. Methotrexate chemosensitivity by ATP luminescence in human leukaemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anti-Cancer Drugs 1995; 6: 398-404.
22. Hunter EM, Sutherland IA, Cree IA, et al. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anti-Cancer Drugs 1994; 5: 171-6.
23. Bonadonna G, Valagussa P. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience. Surg Oncol Clin N Am 1995; 4: 701-14.
24. Hudis C, Seidman A, Raptis C, et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996; 23: 58-64.
25. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, et al. Specific F53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-4.
26. Delia D, Mizutuni S, Lamorte C, Goi K, Iwata S, Pierotti MA. p53 activity and chemotherapy. Nat Med 1996; 2: 724-5.
27. Steel M. Cancer genes: complexes and complexities. Lancet 1993; 342: 754-5.
28. Hamm JT, Allegra JC. Hormonal therapy. In: Moosa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology, 2nd edn. Baltimore: Williams & Wilkins 1991: 597-600.
29. Zeigler LD, Connelly JH, Frye D, Smith TL, Hortobagyi G GN. Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer. Cancer 1991; 68: 628-3.3.
30. Kernohan NM, Cox LS. Immunochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.
31. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 1992; 44: 690-708.
32. Bosanquet AG. In vitro drug sensitivity testing for the individual testing: an adjunct to current methods of treatment choice. Clin Oncol 1993; 5: 195-7.
33. Cree IA, Petty RD, Kurbacher CM, Untch M. Comments on tumor chemosensitivity and chemoresistance assays. Cancer 1996; 78: 2031-2.
34. Von Hoff DD. He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 1990; 82: 96-101.
35. Welander CE, Homesley HD, Jobson VW. In vitro chemotherapy testing of gynecologic tumors: basis for planning therapy? Am J Obstet Gynecol 1983; 147: 188-95.
36. Von Hoff DD, Kronmal R, Salmon SE, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991; 67: 20-7.
37. Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. Principles Practice Oncol 1993; 7: 1-16.
38. Cree IA, Petty RD, Sutherland LA, et al. Elucidation of molecular determinants of tumor chemosensitivity by ATP-based luminescence assay. In: Campbell AC, Stanley PE, Kricka LJ, eds. Chemluminescence and bioluminescence. Chichester: John Wiley 1994; 407-410.
39. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metast Rev 1994; 13: 209-22.
40. Maehara Y, Anai H, Tamada R, Sugimachi K. The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 1987; 23: 273-6.
41. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolum Chemilum 1995; 10: 29-34.
42. Hanauske AR. In vitro assays for antitumor activity: more pitfalls to come? Eur J Cancer 1993; 29A: 1502-3.
43. Pacliacci MC, Spinozzi F, Migliorati G, et al. Genistein inhibits tumor cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 1993; 29A: 1573-7.
44. Kaspers GJL, Pieters R, Van Zantwijk CH, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-74.
45. Mitsuhashi Y, Inaba M, Sugiyama Y, Kobayashi T. In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toard cell cytlce phae-nonspecinc agents under the clnically equivalent area under the curve. Cancer 1992; 70: 2540-6.
46. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1: 305-11.
47. Hoffman RM. Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 1991; 3: 86-92.
48. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 1996; 87: 1962-71.
49. Shaw GL, Gazdar AF, Phelps R et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 1993; 53: 5181-7.
50. Frankfurt OS. Detection of apoptosis in leukemic and breast cancer cells with monoclonal antibody to single-stranded DNA. Anticancer Res 1994; 14: 1861-9.
51. Csoka K, Nygren P, Graf W, Pahlman L, Glimelius B, Larsson R. Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Int J Cancer 1995; 63: 356-60.
52. Maurer HR. In vitro screening for potential anti-cancer drugs; new approaches including induction of differentiation. In: Crommelin D, Couvreur P, Duchene D, eds. In vitro and ex vivo test systems to rationalize drug design and delivery. Paris: Editions de Sante 1994; 99-107.
53. Andreotti PE, Thornthwaite JT, Morse IS. ATP Tumor chemosensitivity assay. In Stanley PE, Kricka LJ, eds. Bioluminescence and chemiluminescence: current status. Chichester: John Wiley 1991, 417-20.
54. Andreotti PE, Linder D, Hartmann DM, et al. ATP tumor chemosensitivity assay application for solid tumors and leukaemias. In: Szalay A, Kricka LJ, Stanley PE, eds. Chemiluminescence and bioluminescence: current Status. Chichester: John Wiley 1993: 271-5.
55. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate ATP luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
56. Kurbacher CM, Nagel W, Mailman P, et al. In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents. Anticancer Res 1994; 14: 1529-34.
57. Kurbacher CM, Cree IA, Brenne U, et al. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by microplate ATP bioluminescence assay. Breast Can Res Treat 1996; 41: 161-70.
58. Lundin A, Hasenson M, Persson J, Pousette A. Estimation of biomass in growing cell lines by adenosine triphosphate assay. Methods Enzymol 1986; 133: 27-42.
59. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984; 62: 338-43.
60. Garewal HS, Ahmann F, Schifman RB, Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst 1986; 77: 1039-45.
61. Sevin BU, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer 1993; 71: 1613-20.
62. Hirai T, Kawano K, Hirabayashi N, et al. A novel in vitro chemosensitivity test using materials collected by endoscopie biopsy. Anti-Cancer Drugs 1991; 2: 269-74.
63. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 1996; 7: 630-5.
64. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer 1996; 77: 1020-5.
65. Alberts DS, Salmon SE, Moon TE. Human tumor cloning: drug sensitivity testing clinical correlations. Prog Clin Cancer 1982; 8: 147-79.
66. Daniels JR, Daniels AM, Luck EE, Whitman B. Casagrande JT, Skinner DG. Chemosensitivity of human neoplasms with in vitro clone formation. Experience at the University of Southern California - Los Angeles County Medical Center. Cancer Chemother Pharmacol 1981; 6: 245-51.
67. Federico M, Alberts DS, Garcia DJ, et al. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecol Oncol 1994; 55: S156-63.
68. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461-3.
69. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321-7.
70. Von Hoff DO, Cowan J, Harris G, Reisdorf G. Human tumor cloning: feasibility and clinical correlation. Cancer Chemother Pharmacol 1981; 6: 265-71.
71. Von Hoff DD, Sandbach JF, Clark CM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
72. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 1985; 45: 5436-41.
73. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82: 582-8.
74. Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology 1991; 5: 93-103.
75. Bosanquet AG, Bird MC, Price WJP, Gilby ED. An assessment of a short term tumor chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer 1983; 47: 781-9.
76. Bosanquet AG. Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test results with both patient response and survival. Forum Trends Exp Clin Med 1994; 4: 179-95.
77. Meitner PA. The fluorescent cytoprint assay: a new approach to in vitro chemosensitivity testing. Oncology 1991; 5: 75-81.
78. Klumper E, Pieters R, Kaspers GJ, et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 1995; 9: 1864-9.